Home

The Eyquem lab is a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.

Learn more

Our Research

Our laboratory is aimed at understanding the current limitations of CAR T cell therapy using innovative tumor models and functional genomics and overcoming these challenges by reprogramming T cells with the use of genome editing and synthetic receptors.

Our Partners

Eyquem-OurPeople2

Our People

The Eyquem lab is a highly collaborative group passionate about using synthetic immunology to advance adoptive cell therapies.
Learn More

News

Media highlights of Eyquem Lab's research.
Peptide–RNP delivery paper highlighted by Nature Reviews Bioengineering
Read More >>
Peptide–RNP delivery paper highlighted by Nature Biomedical Engineering
Read More >>
HIT-T cell paper highlighted in Cancer Cell
Read More >>
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors
Read More >>
CRISPR-driven CARs
Read More >>
CRISPR genome editing and immunotherapy – the early adopter
Read More >>
CRISPR gene therapy is enhancing T-cell immunotherapy treatment of cancer and treatments in people could be available within 2 to 3 years
Read More >>
Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors
Read More >>
Using CRISPR to Supercharge Cancer-Killing Immune Cells
Read More >>
AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies
Read More >>
Curing Cancer with CRISPR
Read More >>
Pancreatic cancer cells digest extracellular protein
Read More >>

Stay Updated

Keep up-to-date with the latest research from the Eyquem lab.

Follow us on Twitter

Sign up for Newsletter

Twitter feed is not available at the moment.

Recent Lab News

June 2021

Joe Muldoon was selected for the Cancer Research Institute Irvington Postdoctoral Fellowship

December 2020

Vincent Allain was selected for the ARC foundation International Mobility Award 

August 2020

William Nyberg was selected for the Swedish Society for Medical Research fellowship

December 2019

Alexis Talbot was selected for the Fondation de France Fellowship